02096.HK
Simcere Pharmaceutical Group Limited
HKSE · Healthcare · Biotechnology · CN
HKD 11.63
−1.19%Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 21, 2026, 07:27 UTC
Simcere Pharmaceutical announced that Zhou Yunshu stepped down as CEO and was appointed President, while founder Ren Jinsheng resumed the role of CEO, effective August 20, 2026.
Source:Aug 20, 2026, 03:05 UTC
Simcere Pharmaceutical announced a strategic partnership with Ruiyang (Shandong) Biopharmaceutical to obtain exclusive commercialization rights in Greater China for the novel biologic drug Kuleweibai injection.